News

Video

Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer

Fact checked by:

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Treatment with Krazati (adagrasib) plus Erbitux (cetuximab) demonstrated meaningful efficacy in heavily pretreated patients with KRAS G12C–mutant unresectable or metastatic colorectal cancer, according to phase 1/2 KRYSTAL-1 trial data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.

Dr. Nataliya Uboha is a medical oncologist at UW Health, as well as an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, and shared her insights on the trial in an interview with CURE.

Glossary:

Overall response rate: the percentage of patients who have a complete or partial response to a treatment.

Disease control rate: the percentage of patients who have a complete, partial or stable response to a cancer treatment.

At a median follow-up of 20.4 months, the overall response rate was 34% by blinded independent central review and 43% by investigator assessment. Disease control rates were 85% and 86%, respectively.

In the interview, Uboha sat down to discuss the KRYSTAL-1 study and highlighted what makes Krazati combined with Erbitux safe when compared to other treatment regimens such as Vectibix.

Transcript:

This a very important question, because when we give treatments to our patients, even if the treatment is very active, if it has a lot of side effects, it is hard to deliver these treatments, or harder for patients to tolerate. The good news is that this regimen is pretty well tolerated. We are seeing some gastrointestinal side effects, in particular nausea, so some patients will need to take anti-nausea medications before taking Krazati [adagrasib].

We've seen a little bit of diarrhea as well with the anti-EGFR drugs that are already approved for colorectal cancer. Notably, Erbitux [cetuximab], Vectibix [panitumumab] are notorious for causing rashes, but we’ve not seen as much of a rash with these drugs when we combine them with Krazati [adagrasib] in the study, but this is something else to look for. In contrast to chemotherapy, these agents do not cause significant suppression in the immune system, so that's the differentiating side effect between this combination and chemotherapy.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content